Drug Search Results
More Filters [+]

BMS-986202

Alternative Names: bms-986202, bms986202, bms 986202
Latest Update: 2023-09-29
Latest Update Note: News Article

Product Description

A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2; a pyridazine carboxamide-derived Tyk2 JH2 ligand as a clinical Tyk2 inhibitor currently in late development for the treatment of psoriasis (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33370104/)

Mechanisms of Action: TYK2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BMS-986202

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Psoriasis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IM016-006

P1

Completed

Psoriasis

2016-12-15

Recent News Events